Professor, the University of Otago, Co-director, Genomics Aotearoa
Jon joined Neuren in 2013 as CFO and has been CEO since May 2020. He has played a central role in all aspects of Neuren’s R&D, commercial and corporate activities for 10 years. Before joining Neuren he was a member of the leadership team at Acrux throughout a period that included Acrux’s IPO and listing on the ASX, the development and FDA approval of three novel pharmaceutical products and a transforming licensing deal with Eli Lilly in 2010.
He formerly spent seven years in a series of senior financial positions in the R&D and corporate functions of international pharmaceutical groups Medeva and Celltech, which are now part of UCB. Jon is a Chartered Accountant and holds a degree in Biotechnology from the University of Reading in the UK.